Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;8(Suppl 2):S204-S207.
doi: 10.21037/tcr.2019.03.03.

Massively parallel sequencing of urinary DNA-the dawn of non-invasive bladder cancer detection and surveillance?

Douglas G Ward  1 , Richard T Bryan  1
Affiliations
Editorial

Massively parallel sequencing of urinary DNA-the dawn of non-invasive bladder cancer detection and surveillance?

Douglas G Ward et al. Transl Cancer Res. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.03.03). RT Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. DG Ward has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Comparison of cfDNA and cpDNA extraction, properties and analysis. Both types of DNA are compatible with most analytical methods although short amplicons must be used in PCR-based approaches with cfDNA due to its fragmented nature. cfDNA, cell-free DNA; cpDNA, cell-pellet DNA; SMs, somatic mutations; SNVs, single nucleotide variants; CNVs, copy number variants; NGS, next generation sequencing; SNPs, single nucleotide polymorphisms; SWGS, shallow whole genome sequencing.
See this image and copyright information in PMC

Comment on

  • Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.
    Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri AA, Stehr H, Liu CL, Lim H, Costa HA, Nabet BY, Sin MLY, Liao JC, Alizadeh AA, Diehn M. Dudley JC, et al. Cancer Discov. 2019 Apr;9(4):500-509. doi: 10.1158/2159-8290.CD-18-0825. Epub 2018 Dec 21. Cancer Discov. 2019. PMID: 30578357 Free PMC article.

References

    1. Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discov 2018. [Epub ahead of print]. 10.1158/2159-8290.CD-18-0825 - DOI - PMC - PubMed
    1. Bessa A, Maclennan S, Enting D, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019. [Epub ahead of print]. 10.1016/j.eururo.2019.01.031 - DOI - PubMed
    1. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int 2015;94:1-24. 10.1159/000369357 - DOI - PubMed
    1. Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 2018;174:1033. 10.1016/j.cell.2018.07.036 - DOI - PMC - PubMed
    1. Feber A, Dhami P, Dong L, et al. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics 2017;9:8. 10.1186/s13148-016-0303-5 - DOI - PMC - PubMed